ALK inhibitor: Difference between revisions
Content deleted Content added
→Clinical trials: add ref |
Rescuing 1 sources and tagging 0 as dead. #IABot (v1.4beta3) |
||
| Line 27: | Line 27: | ||
==NPM-ALK== |
==NPM-ALK== |
||
NPM-ALK is a different variation/fusion of [[Anaplastic lymphoma kinase|ALK]] that drives [[anaplastic large-cell lymphoma]]s (ALCLs) and is the target of other ALK inhibitors.<ref>{{cite web |url=http://www.pnas.org/content/104/1/270.short |title=Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK |year=2007 |author=Galkin|display-authors=etal}}</ref> |
NPM-ALK is a different variation/fusion of [[Anaplastic lymphoma kinase|ALK]] that drives [[anaplastic large-cell lymphoma]]s (ALCLs) and is the target of other ALK inhibitors.<ref>{{cite web |url=http://www.pnas.org/content/104/1/270.short |title=Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK |year=2007 |author=Galkin|display-authors=etal}}</ref> |
||
<ref>http://www.axonmedchem.com/product/1416tae684.html</ref> |
<ref>{{cite web|url=http://www.axonmedchem.com/product/1416tae684.html |title=Archived copy |accessdate=2010-10-02 |deadurl=yes |archiveurl=https://web.archive.org/web/20101223114058/http://www.axonmedchem.com/product/1416tae684.html |archivedate=2010-12-23 }}</ref> |
||
==References== |
==References== |
||
Revision as of 01:30, 24 June 2017
ALK inhibitors are potential anti-cancer drugs that act on tumours with variations of anaplastic lymphoma kinase (ALK) such as an EML4-ALK translocation.[1]
EML4-ALK
About 4-7% of non-small cell lung carcinomas (NSCLC) have EML4-ALK translocations.[2]
Approved inhibitors
- crizotinib (Xalkori) and ceritinib (Zykadia), approved by the FDA for treatment of NSCLC.[2][3][4]
- Alectinib (Alecensa) (Chugai, NDA has been filed in Japan) (breakthrough status in U.S.) FDA approved Dec 2015.
Clinical trials
 | This section needs to be updated. (February 2016) |
Additional ALK inhibitors currently (or soon to be) undergoing clinical trials include:
- Dalantercept, ACE-041 (Acceleron)[5]
- Brigatinib (AP26113) (by Ariad) (breakthrough status in U.S.) (also an EGFR inhibitor)
- Entrectinib (Nerviano's NMS-E628, licensed by Ignyta and renamed RXDX-101, in the U.S. orphan drug designation and rare pediatric disease designation for the treatment of neuroblastoma and orphan drug designation for treatment of TrkA-, TrkB-, TrkC-, ROS1- and ALK-positive NSCLC)
- PF-06463922 (Pfizer)
- TSR-011 (Tesaro)
- CEP-37440 (Teva)
- X-396 (Xcovery)
Updates for several of these will be available at the start of June at ASCO 2014.
Discontinued
NPM-ALK
NPM-ALK is a different variation/fusion of ALK that drives anaplastic large-cell lymphomas (ALCLs) and is the target of other ALK inhibitors.[6] [7]
References
- ^ Nelsen (2010). "ALK Inhibitors: Possible New Treatment for Lung Cancer".
- ^ a b Farmer (2010). "Non-Small-Cell Lung Cancer Standards of Care Challenged by a Cornucopia of New Drugs".
- ^ Chustecka (2010). "Crizotinib in ALK-NSCLC; Response Rate "Unprecedented"".
- ^ "FDA Approves Ceritinib for ALK-Positive Lung Cancer". Medscape. April 29, 2014.
- ^ "Dalantercept". AdisInsight. Retrieved 15 February 2017.
- ^ Galkin; et al. (2007). "Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK".
- ^ "Archived copy". Archived from the original on 2010-12-23. Retrieved 2010-10-02.
{{cite web}}: Unknown parameter|deadurl=ignored (|url-status=suggested) (help)CS1 maint: archived copy as title (link)